maftivimab
E468964
Maftivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
All labels observed (2)
| Label | Occurrences |
|---|---|
| maftivimab canonical | 4 |
| atoltivimab | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4784926 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: maftivimab Context triple: [REGN-EB3, hasComponent, maftivimab]
-
A.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
-
B.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
-
C.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
D.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
-
E.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: maftivimab Target entity description: Maftivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
-
A.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
-
B.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
-
C.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
D.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
-
E.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
- F. None of above. chosen
Statements (43)
| Predicate | Object |
|---|---|
| instanceOf |
Ebola virus treatment
ⓘ
monoclonal antibody ⓘ therapeutic antibody ⓘ |
| actsSynergisticallyWith |
atoltivimab
ⓘ
linked to:
odesivimab
odesivimab ⓘ |
| approvalYear | 2020 ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| belongsToDrugClass |
antiviral monoclonal antibodies
ⓘ
immunoglobulins ⓘ |
| componentOf | fixed-dose combination with atoltivimab and odesivimab ⓘ |
| developedBy | Regeneron Pharmaceuticals ⓘ |
| hasATCCode | J06BD53 ⓘ |
| hasCASNumber | 2098781-36-4 ⓘ |
| hasINN | maftivimab ⓘ |
| hasLegalStatus | prescription-only medicine ⓘ |
| hasMolecularTarget |
Ebola virus glycoprotein
ⓘ
Zaire ebolavirus glycoprotein ⓘ |
| hasPharmacologicalEffect |
improvement of survival in Ebola virus disease patients
ⓘ
reduction of Ebola virus load ⓘ |
| hasUNII | 0YH6ZK4Z4E ⓘ |
| indication |
treatment of infection caused by Zaire ebolavirus in adults
ⓘ
treatment of infection caused by Zaire ebolavirus in children ⓘ treatment of infection caused by Zaire ebolavirus in neonates born to infected mothers ⓘ |
| isHumanized | true ⓘ |
| isMarketedAs | Inmazeb (in combination with atoltivimab and odesivimab) ⓘ |
| isNotIndicatedFor |
post-exposure prophylaxis of Ebola virus disease
ⓘ
pre-exposure prophylaxis of Ebola virus disease ⓘ |
| isUsedIn | hospital setting ⓘ |
| mechanismOfAction | binds to Ebola virus glycoprotein and neutralizes viral entry into host cells ⓘ |
| origin | recombinant DNA technology ⓘ |
| partOf |
Inmazeb
ⓘ
REGN-EB3 antibody cocktail ⓘ
linked to:
REGN-EB3
|
| pregnancyCategory | insufficient human data ⓘ |
| regimen | single-dose intravenous infusion as part of fixed-dose combination ⓘ |
| risk |
hypersensitivity reactions
ⓘ
infusion-related reactions ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targetOrganism | Zaire ebolavirus ⓘ |
| therapyType | passive immunotherapy ⓘ |
| usedFor |
treatment of Ebola virus disease
ⓘ
treatment of Zaire ebolavirus infection ⓘ |
| usedWith |
atoltivimab
ⓘ
odesivimab ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: maftivimab Description of subject: Maftivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: maftivimab